As filed with the Securities and Exchange Commission on March 1, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
Form S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
_______________________________
Syndax Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
_______________________________
| |
Delaware | 32-0162505 |
(State or other jurisdiction of incorporation or organization) | (IRS employer identification number) |
35 Gatehouse Drive
Building D, Floor 3
Waltham, Massachusetts 02451
(781) 419-1400
(Address of principal executive offices)
_______________________________
2015 Omnibus Incentive Plan
2015 Employee Stock Purchase Plan
(Full titles of the plans)
_______________________________
Michael A. Metzger
Chief Executive Officer
Syndax Pharmaceuticals, Inc.
35 Gatehouse Drive
Building D, Floor 3
Waltham, Massachusetts 02451
(781) 419-1400
(Name, address and telephone number of agent for service)
Laura A. Berezin Jaime L. Chase Cooley LLP 3175 Hanover Street Palo Alto, CA 94304 (650) 843-5000 | Luke J. Albrecht Senior Vice President, General Counsel & Secretary Syndax Pharmaceuticals, Inc. Building D, Floor 3 35 Gatehouse Drive Waltham, Massachusetts 02451 (781) 419-1400 |
_______________________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| |
Large accelerated filer ☒ | Accelerated filer ☐ |
Non-accelerated filer ☐ | Smaller reporting company ☐ |
Emerging growth company ☐ | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by References
The Registrant is filing this Registration Statement for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.
The Registrant previously registered shares of its Common Stock for issuance under the 2015 Plan and the ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 25, 2016 (File No. 333-210412), August 25, 2017 (File No. 333-220172), August 8, 2018 (File No. 333-226678), August 7, 2019 (File No. 333-233083), August 6, 2020 (File No. 333-241654) and August 9, 2021 (File No. 333-258628). Pursuant to General Instruction E to Form S-8, this Registration Statements hereby incorporates by reference the contents of the Registration Statements referenced above.
Item 8. Exhibits
The exhibits to this Registration Statement are listed below and incorporated by reference herein.
Exhibit
Number | Exhibit Description |
4.1 | Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, SEC File No. 001-37708, filed with the SEC on March 8, 2016). |
4.2 | Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, SEC File No. 001-37708, filed with the SEC on March 8, 2016). |
4.3 | Specimen common stock certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A, SEC File No. 333-208861, filed with the SEC on February 10, 2016). |
4.4 | 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 4.13 to the Company’s Registration Statement on Form S-8, SEC File No. 333-210412, as filed with the SEC on March 25, 2016). |
4.5 | Form of Incentive Stock Option Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.13 to the Registrant’s Registration Statement on Form S-1, SEC File No. 333-208861, filed with the SEC on January 4, 2016). |
4.6 | Form of Non-Qualified Option Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.14 to the Registrant’s Registration Statement on Form S-1, SEC File No. 333-208861, filed with the SEC on January 4, 2016). |
4.7 | Form of Stock Unit Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, SEC File No. 001-37708, as filed with the SEC on August 6, 2020). |
4.8 | Form of Deferred Settlement Stock Unit Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K, SEC File No. 001-37708, filed with the SEC on March 12, 2021). |
4.9 | 2015 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 4.16 to the Company’s Registration Statement on Form S-8, SEC File No. 333-210412, as filed with the SEC on March 25, 2016). |
5.1 | Opinion of Cooley LLP. |
\\039610/000004 - 1425655 v4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Waltham, Commonwealth of Massachusetts, on March 1, 2022.
Syndax Pharmaceuticals, Inc.
By: /s/ Michael A. Metzger
Michael A. Metzger
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael A. Metzger and Luke J. Albrecht, and each of them, his true and lawful attorney-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | | Title | | Date |
| | | | |
/s/ Michael A. Metzger | | Chief Executive Officer and Director (Principal Executive Officer) | | March 1, 2022 |
Michael A. Metzger | | | | |
| | | | |
/s/ Alexander Nolte | | Chief Accounting Officer (Principal Accounting Officer, Interim Principal Financial Officer) | | March 1, 2022 |
Alexander Nolte | | | | |
| | | | |
/s/ Dennis G. Podlesak | | Chairman of the Board of Directors | | March 1, 2022 |
Dennis G. Podlesak | | | | |
| | | | |
/s/ Martin H. Huber, M.D. | | Director | | March 1, 2022 |
Martin H. Huber, M.D. | | | | |
| | | | |
/s/ Jennifer Jarrett | | Director | | March 1, 2022 |
Jennifer Jarrett | | | | |
| | | | |
/s/ Keith A. Katkin | | Director | | March 1, 2022 |
Keith A. Katkin | | | | |
| | | | |
/s/ Pierre Legault | | Director | | March 1, 2022 |
Pierre Legault | | | | |
| | | | |
/s/ William Meury | | Director | | March 1, 2022 |
William Meury | | | | |
Signature | | Title | | Date |
| | | | |
/s/ Briggs W. Morrison, M.D. | | President Head of Research & Development, Director | | March 1, 2022 |
Briggs W. Morrison, M.D. | | | | |
